A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study adopts a randomized, open‐label, positive‐controlled, multicenter design,aiming to evaluate the efficacy and safety of SHR‐A1811 in combination with chemotherapyand bevacizumab versus standard therapy as first‐line treatment for advanced colorectalcancer, and to explore the drug's immunogenicity and pharmacokinetic characteristics.
Epistemonikos ID: 7b8eabe919d673b66d5c298fb35f619441d0ea43
First added on: Jun 30, 2026